SC Diabetologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
SC Diabetologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Nutr Metab Cardiovasc Dis. 2022 Jul;32(7):1719-1724. doi: 10.1016/j.numecd.2022.03.031. Epub 2022 Apr 13.
The new advanced hybrid closed loop insulin infusion systems have the potential to significantly improve glycaemic control. The aim of this study was to evaluate the effectiveness of the Minimed 780G system in 59 patients with type 1 diabetes.
Glucose control obtained by using the system in automatic mode at 1-2 months of activation, at 2-4 months, at 4-6 months, and beyond 6 month was compared with those obtained with the system in manual mode. A significant improvement in time-in-range and in time-above-range throughout the follow-up was observed, as well as a significant reduction in time-below-range (<54 mg/dl) after 6 months, a significant reduction of the glucose variability and of HbA1c. After switching the mode, all target percentages lied on the average within the recommended ranges by literature consensus and no severe hypoglycemia nor ketoacidosis episodes were recorded.
The Minimed 780G allowed a rapid and progressive improvement of the overall glucose control.
新型高级混合闭环胰岛素输注系统有可能显著改善血糖控制。本研究的目的是评估 Minimed 780G 系统在 59 例 1 型糖尿病患者中的有效性。
在激活后 1-2 个月、2-4 个月、4-6 个月和 6 个月以上的自动模式下，使用该系统获得的血糖控制与手动模式下获得的血糖控制进行了比较。在整个随访过程中，时间范围和时间范围以上都有显著改善，6 个月后时间范围以下（<54mg/dl）显著减少，血糖变异性和 HbA1c 显著降低。切换模式后，所有目标百分比平均均在文献共识推荐范围内，且未记录到严重低血糖或酮症酸中毒发作。
Minimed 780G 可快速、持续改善整体血糖控制。
